The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Transthyretin Amyloidosis (ATTR)-Global Market Insights and Sales Trends 2025
Synopsis
Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point mutations within TTR allele, wild-type ATTR is caused by the misfolding of Wild-Type TTR. Major prevalence of Hereditary ATTR is observed in the 7MM, and this type has been further sub-classified into Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis Cardiomyopathy (FAC).
The global Transthyretin Amyloidosis (ATTR) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Transthyretin Amyloidosis (ATTR) in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers and Diagnostic Centers,, are propelling Transthyretin Amyloidosis (ATTR) market. Hereditary ATTR (HATTR), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Wild-Type (WT) ATTR segment is estimated at % CAGR for the next seven-year period.
United States accounts for highest ATTR Amyloidosis Cases, followed by EU5 (Italy, France, Spain, Germany, UK) and Japan.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Transthyretin Amyloidosis (ATTR), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Transthyretin Amyloidosis (ATTR) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Transthyretin Amyloidosis (ATTR) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Transthyretin Amyloidosis (ATTR) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Transthyretin Amyloidosis (ATTR) covered in this report include Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Corino Therapeutics, Proclara Bioscience and Arcturus Therapeutics, etc.
The global Transthyretin Amyloidosis (ATTR) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Global Transthyretin Amyloidosis (ATTR) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Transthyretin Amyloidosis (ATTR) market, Segment by Type:
Hereditary ATTR (HATTR)
Wild-Type (WT) ATTR
Global Transthyretin Amyloidosis (ATTR) market, by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Transthyretin Amyloidosis (ATTR) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point mutations within TTR allele, wild-type ATTR is caused by the misfolding of Wild-Type TTR. Major prevalence of Hereditary ATTR is observed in the 7MM, and this type has been further sub-classified into Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis Cardiomyopathy (FAC).
The global Transthyretin Amyloidosis (ATTR) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Transthyretin Amyloidosis (ATTR) in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers and Diagnostic Centers,, are propelling Transthyretin Amyloidosis (ATTR) market. Hereditary ATTR (HATTR), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Wild-Type (WT) ATTR segment is estimated at % CAGR for the next seven-year period.
United States accounts for highest ATTR Amyloidosis Cases, followed by EU5 (Italy, France, Spain, Germany, UK) and Japan.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Transthyretin Amyloidosis (ATTR), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Transthyretin Amyloidosis (ATTR) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Transthyretin Amyloidosis (ATTR) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Transthyretin Amyloidosis (ATTR) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Transthyretin Amyloidosis (ATTR) covered in this report include Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Corino Therapeutics, Proclara Bioscience and Arcturus Therapeutics, etc.
The global Transthyretin Amyloidosis (ATTR) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Global Transthyretin Amyloidosis (ATTR) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Transthyretin Amyloidosis (ATTR) market, Segment by Type:
Hereditary ATTR (HATTR)
Wild-Type (WT) ATTR
Global Transthyretin Amyloidosis (ATTR) market, by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Transthyretin Amyloidosis (ATTR) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Transthyretin Amyloidosis (ATTR)
1.1 Transthyretin Amyloidosis (ATTR) Market Overview
1.1.1 Transthyretin Amyloidosis (ATTR) Product Scope
1.1.2 Transthyretin Amyloidosis (ATTR) Market Status and Outlook
1.2 Global Transthyretin Amyloidosis (ATTR) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Transthyretin Amyloidosis (ATTR) Market Size by Region (2018-2029)
1.4 Global Transthyretin Amyloidosis (ATTR) Historic Market Size by Region (2018-2023)
1.5 Global Transthyretin Amyloidosis (ATTR) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Transthyretin Amyloidosis (ATTR) Market Size (2018-2029)
1.6.1 North America Transthyretin Amyloidosis (ATTR) Market Size (2018-2029)
1.6.2 Europe Transthyretin Amyloidosis (ATTR) Market Size (2018-2029)
1.6.3 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size (2018-2029)
1.6.4 Latin America Transthyretin Amyloidosis (ATTR) Market Size (2018-2029)
1.6.5 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size (2018-2029)
2 Transthyretin Amyloidosis (ATTR) Market by Type
2.1 Introduction
2.1.1 Hereditary ATTR (HATTR)
2.1.2 Wild-Type (WT) ATTR
2.2 Global Transthyretin Amyloidosis (ATTR) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Transthyretin Amyloidosis (ATTR) Historic Market Size by Type (2018-2023)
2.2.2 Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Transthyretin Amyloidosis (ATTR) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Transthyretin Amyloidosis (ATTR) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Transthyretin Amyloidosis (ATTR) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue Breakdown by Type (2018-2029)
3 Transthyretin Amyloidosis (ATTR) Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Centers
3.1.3 Diagnostic Centers
3.2 Global Transthyretin Amyloidosis (ATTR) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Transthyretin Amyloidosis (ATTR) Historic Market Size by Application (2018-2023)
3.2.2 Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Transthyretin Amyloidosis (ATTR) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Transthyretin Amyloidosis (ATTR) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Transthyretin Amyloidosis (ATTR) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue Breakdown by Application (2018-2029)
4 Transthyretin Amyloidosis (ATTR) Competition Analysis by Players
4.1 Global Transthyretin Amyloidosis (ATTR) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Transthyretin Amyloidosis (ATTR) as of 2022)
4.3 Date of Key Players Enter into Transthyretin Amyloidosis (ATTR) Market
4.4 Global Top Players Transthyretin Amyloidosis (ATTR) Headquarters and Area Served
4.5 Key Players Transthyretin Amyloidosis (ATTR) Product Solution and Service
4.6 Competitive Status
4.6.1 Transthyretin Amyloidosis (ATTR) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Transthyretin Amyloidosis (ATTR) Products, Services and Solutions
5.1.4 Pfizer Transthyretin Amyloidosis (ATTR) Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Alnylam Pharmaceuticals
5.2.1 Alnylam Pharmaceuticals Profile
5.2.2 Alnylam Pharmaceuticals Main Business
5.2.3 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Products, Services and Solutions
5.2.4 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue (US$ Million) & (2018-2023)
5.2.5 Alnylam Pharmaceuticals Recent Developments
5.3 Ionis Pharmaceuticals
5.3.1 Ionis Pharmaceuticals Profile
5.3.2 Ionis Pharmaceuticals Main Business
5.3.3 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Products, Services and Solutions
5.3.4 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue (US$ Million) & (2018-2023)
5.3.5 Corino Therapeutics Recent Developments
5.4 Corino Therapeutics
5.4.1 Corino Therapeutics Profile
5.4.2 Corino Therapeutics Main Business
5.4.3 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Products, Services and Solutions
5.4.4 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue (US$ Million) & (2018-2023)
5.4.5 Corino Therapeutics Recent Developments
5.5 Proclara Bioscience
5.5.1 Proclara Bioscience Profile
5.5.2 Proclara Bioscience Main Business
5.5.3 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Products, Services and Solutions
5.5.4 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue (US$ Million) & (2018-2023)
5.5.5 Proclara Bioscience Recent Developments
5.6 Arcturus Therapeutics
5.6.1 Arcturus Therapeutics Profile
5.6.2 Arcturus Therapeutics Main Business
5.6.3 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Products, Services and Solutions
5.6.4 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue (US$ Million) & (2018-2023)
5.6.5 Arcturus Therapeutics Recent Developments
6 North America
6.1 North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Transthyretin Amyloidosis (ATTR) Market Dynamics
11.1 Transthyretin Amyloidosis (ATTR) Industry Trends
11.2 Transthyretin Amyloidosis (ATTR) Market Drivers
11.3 Transthyretin Amyloidosis (ATTR) Market Challenges
11.4 Transthyretin Amyloidosis (ATTR) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
